On February 1st I participated in the First World Congress in Controversies in Urology (CURy), that was held in Barcelona, Spain. Here I had two commitments. One, to present the poster with the first results of the prospective multicentric study of the IGLU Group (International Greenlight Users), with the results of the Greenlight HPS 120 watt laser in patients in urinary retention, under anticoagulation, and with big prostates, that I copy below.
Another one, to participate in a debate where we addressed what was the best treatment for BPH. TURP (Transurethral resection of the prostate), the treatment with the Greenlight HPS laser or the Holmium laser enucleation of the prostate (HoLEP). In this session I confronted Prof. Marberger (who defended TURP), and Prof. Montorsi, the current editor of European Urology (who defended HoLEP) It was an interesting and intense debate, where I think it was clear that TURP continues to have a considerable morbidity and even mortality, and that the technical difficulty of HoLEP limits seriously its clinical use, the learning curve is too long. The Greenlight laser emerges as a treatment option that is very advantageous for the patients, due to its high efficacy and minimum morbidity... There are 1600 greenlight laser units worldwide and more than 300.000 patients have been treated.
In this photo, speaking, sitting by Dr. Montorsi (Italy) and Dr. Marberger (Austria)...
In this photo, Dr. Lepor (USA) and Dr. Djavan (Austria), who moderated the session.
No comments:
Post a Comment